- Home
- CEV vs UNCY Comparison
CEV vs UNCY Comparison
Compare CEV & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- UNCY
- Stock Information
- Founded
- CEV 1999
- UNCY 2016
- Country
- CEV United States
- UNCY United States
- Employees
- CEV N/A
- UNCY N/A
- Industry
- CEV Finance/Investors Services
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- UNCY Health Care
- Exchange
- CEV Nasdaq
- UNCY Nasdaq
- Market Cap
- CEV 66.8M
- UNCY 74.2M
- IPO Year
- CEV N/A
- UNCY 2021
- Fundamental
- Price
- CEV $9.91
- UNCY $3.87
- Analyst Decision
- CEV
- UNCY Strong Buy
- Analyst Count
- CEV 0
- UNCY 4
- Target Price
- CEV N/A
- UNCY $63.75
- AVG Volume (30 Days)
- CEV 19.6K
- UNCY 527.4K
- Earning Date
- CEV 01-01-0001
- UNCY 11-12-2025
- Dividend Yield
- CEV 4.23%
- UNCY N/A
- EPS Growth
- CEV N/A
- UNCY N/A
- EPS
- CEV 0.36
- UNCY N/A
- Revenue
- CEV N/A
- UNCY N/A
- Revenue This Year
- CEV N/A
- UNCY N/A
- Revenue Next Year
- CEV N/A
- UNCY $3,131.28
- P/E Ratio
- CEV $29.36
- UNCY N/A
- Revenue Growth
- CEV N/A
- UNCY N/A
- 52 Week Low
- CEV $8.83
- UNCY $3.40
- 52 Week High
- CEV $10.91
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- CEV 74.13
- UNCY 34.49
- Support Level
- CEV $9.45
- UNCY $4.23
- Resistance Level
- CEV $10.01
- UNCY $4.43
- Average True Range (ATR)
- CEV 0.06
- UNCY 0.20
- MACD
- CEV 0.05
- UNCY -0.00
- Stochastic Oscillator
- CEV 81.58
- UNCY 8.20
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.